AP
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis (NCT05887908) | Meiji Seika Pharma Co., Ltd. | 2023-05-23 |
Track AP automatically
Every clearance here is in the API, with alerts when new ones post.